Maintenance Therapy Recommendations for Ulcerative Colitis in Remission

First‑Line 5‑ASA Maintenance

Patients who achieve remission with 5‑ASA should continue oral 5‑ASA at a dose of ≥ 2 g/day for ongoing maintenance. The American Gastroenterological Association (AGA) recommends maintaining the same regimen that induced remission. 1
All individuals with ulcerative colitis, particularly those with left‑sided or extensive disease, should receive lifelong maintenance with 5‑ASA at ≥ 2 g/day to sustain remission. (Guideline panel) 2

A higher maintenance dose of 5‑ASA (approximately 2.4 g/day) significantly prolongs remission compared with a lower dose (≈1.2 g/day); the benefit is most pronounced in patients with extensive disease. (Guideline panel) 2
Once‑daily administration of 5‑ASA is as effective as divided dosing and improves medication adherence, making it the preferred schedule. (AGA) 1
For patients who attained remission using combined oral and rectal 5‑ASA (especially those with left‑sided disease or proctitis), both routes should be continued to maintain remission. (AGA) 1

Individuals who required escalation beyond 5‑ASA and achieved remission with biologic agents (e.g., infliximab, adalimumab, golimumab, vedolizumab) or with the Janus‑kinase inhibitor tofacitinib should continue the same biologic or targeted therapy indefinitely for maintenance. (Guideline panel) 3

The AGA recommends against routine continuation of 5‑ASA in patients who are in remission on biologic agents, immunomodulators, or tofacitinib after prior 5‑ASA failure; this suggestion is based on very low‑quality evidence. 4
A meta‑analysis found no difference in the rate of maintained clinical remission between patients receiving TNF‑α antagonists or tofacitinib with versus without concomitant 5‑ASA. (AGA) 4

Patients who achieve corticosteroid‑free remission with thiopurine therapy (azathioprine or 6‑mercaptopurine) should continue thiopurine monotherapy to preserve remission. (AGA) 1
Thiopurines are not indicated for induction of remission but may be employed for maintenance in steroid‑dependent ulcerative colitis. (Guideline panel) 3

Corticosteroids should never be used for maintenance of ulcerative colitis remission because they are ineffective for this purpose and are associated with significant adverse effects (e.g., osteoporosis, infection, metabolic complications). (AGA) 1
Methotrexate monotherapy is ineffective for maintaining remission in ulcerative colitis and should not be employed for this indication. (AGA) 1

Long‑term 5‑ASA therapy may confer a chemoprotective effect against colorectal cancer, providing additional justification for lifelong maintenance; however, sustained remission itself also reduces cancer risk regardless of therapy type. (Guideline panel) 2
In patients with distal disease (proctitis) who have remained in remission for at least two years, discontinuation of medication may be reasonable, although continued 5‑ASA therapy further lowers colorectal cancer risk. (Guideline panel) 2

The American Gastroenterological Association suggests starting with high-dose oral mesalamine (4.8 g/day) combined with rectal mesalamine (at least 1 g/day as an enema) for extensive ulcerative colitis, with the goal of achieving remission within 10-14 days of rectal bleeding or 40 days total 5
High-dose oral mesalamine (4.8 g/day) provides superior efficacy, particularly in extensive colitis, with remission rates significantly better than standard doses (RR 0.75 vs 0.84) 5
Once-daily dosing of oral mesalamine is as effective as divided doses and improves adherence 5, 6
Adding rectal mesalamine (≥1 g/day as enema) to oral mesalamine is superior to oral therapy alone for extensive colitis 5, 6
The standard dose of oral mesalamine is 2.4-3 g/day for mild-to-moderate disease 6, 7

Escalate to corticosteroids if insufficient response after 10-14 days of rectal bleeding or 40 days without complete remission 5
Oral prednisone 40 mg/day is appropriate for moderate-to-severe disease 5, 8
Budesonide MMX 9 mg/day is an alternative with fewer systemic side effects 5, 6
Taper corticosteroids gradually over 8 weeks to avoid adrenal insufficiency 5, 8

The American Gastroenterological Association suggests early use of biologics rather than gradual step-up in patients who value efficacy over the safety profile of 5-ASA 9
TNF-α antagonists (infliximab) can be used at 5 mg/kg IV at weeks 0, 2, 6, then every 8 weeks for maintenance 9
Vedolizumab (integrin antagonist) and ustekinumab (IL-12/23 antagonist) are alternative biologic agents 9
Azathioprine 1.5-2.5 mg/kg/day or mercaptopurine 0.75-1.5 mg/kg/day can be used for steroid-dependent disease 5

Lifelong maintenance with 5-ASA ≥2 g/day is recommended for all patients with extensive UC 5, 10
Higher maintenance doses (2.4 g/day) prolong remission compared to lower doses (1.2 g/day) 10
Discontinuing 5-ASA increases relapse risk; no tapering is required when stopping (unlike corticosteroids) 11
Continue biologic therapy for maintenance after achieving remission 9
The American Gastroenterological Association suggests against continuing 5-ASA in patients on biologics/immunomodulators, though this recommendation is based on very low-quality evidence 9

IV methylprednisolone 40-60 mg/day (not higher doses) is recommended for initial management 9
No adjunctive antibiotics are recommended unless infection is documented 9
Infliximab or cyclosporine can be used as rescue therapy for patients failing IV corticosteroids after 3-5 days 9

Fecal calprotectin should be checked every 6-12 months in patients in remission; escalate therapy if elevated (>150 mg/g) 5
Renal function should be monitored periodically on mesalamine due to rare interstitial nephritis risk 5